期刊文献+

以gp41为靶标的小分子-多肽缀合物作为HIV-1融合抑制剂的设计、合成及活性初筛 被引量:5

Design,Synthesis and Activity Prescreening of Small Molecule-Peptide Conjugates as HIV-1 Fusion Inhibitors Targeting gp41
下载PDF
导出
摘要 芳基吡咯类小分子化合物NB-2衍生物(Noc或Npc)与衍生于C34中的靶标特异性多肽P26所形成的缀合物具有低纳摩尔水平的融合抑制活性.本文通过不同长度或不同柔性的连接臂将Noc或Npc与衍生于C34的靶标特异性多肽P27缀合,探讨了C34中a位残基I635和连接臂对缀合物活性的影响.人体免疫缺陷病毒1型(HIV-1)Env介导的细胞-细胞融合实验结果表明,多肽与小分子之间产生了强的协同作用. HIV-1 fusion inhibitors target the transmembrane subunit( gp41 ) of HIV-1 envelopeglycoproteins. Previous studies had shown that the small molecule pyrrole derivatives, Noc or Npc, can act as a substitute for the pocket binding domain of the C34 peptide, and the small molecule-peptide conjugates exhibit low nanomolar IC50 value in the cell-cell fusion assay. In this paper, pocket-specific small molecule and P27 peptide were covalenfly linked together through specified linkers with different lengths and flexibilities. Small molecule-peptide conjugates exhibited significant inhibitory activity on HIV-1 Env-mediated cell-cell fusion assay.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2014年第10期2100-2103,共4页 Chemical Journal of Chinese Universities
基金 国家自然科学基金(批准号:81373266) '重大新药创制'科技重大专项项目(批准号:2012ZX09301003)资助~~
关键词 人体免疫缺陷病毒1型(HIV-1) 融合抑制剂 缀合物 HIV-1 Fusion inhibitor Conjugate
  • 相关文献

参考文献20

  • 1Simon V.,Ho D.D.,Karim Q.A.,Lancet,2006,368(9534),489-504. 被引量:1
  • 2Kawamura M.,Naito T.,Ueno M.,Akagi T.,Hiraishi K.,Takai I.,Makino M.,Serizawa T.,Sugimura K.,Akashi M.,Baba M.,J.Med.Virol.,2002,66(3),291-298. 被引量:1
  • 3Cole J.L.,Garsky V.M.,Biochem.,2001,40(19),5633-5641. 被引量:1
  • 4Sia S.K.,Carr P.A.,Cochran A.G.,Malashkevich V.N.,Kim P.S.,Proc.Natl.Acad.Sci.USA,2002,99(23),14664-14669. 被引量:1
  • 5Cai L.F.,Jiang S.B.,ChemMedChem,2010,5(11),1813-1824. 被引量:1
  • 6Otaka A.,Nakamura M.,Nameki D.,Kodama E.,Uchiyama S.,Nakamura S.,Nakano H.,Tamamura H.,Kobayashi Y.,Matsuoka M.,Fujii N.,Angew.Chem.Int.Ed.,2002,41(16),2937-2940. 被引量:1
  • 7Chen C.H.,Greenberg M.L.,Bolognesi D.P.,Matthews T.J.,AIDS Res.Hum.Retroviruses,2000,16(8),2037-2041. 被引量:1
  • 8Cleveland S.M.,McLain L.,Cheung L.,Jones T.D.,Hollier M.,Dimmock N.J.,J.Gen.Virol.,2003,84(3),591-602. 被引量:1
  • 9史卫国,贾启燕,刘克良.HIV-1融合抑制剂研究现状及发展趋势[J].药学学报,2010,45(2):184-193. 被引量:3
  • 10Zhou J.,Zhang Z.,Mi Z.,Wang X.,Zhang Q.,Li X.,Liang C.,Cen S.,Biochemi.,2012,51(6),1288-1296. 被引量:1

二级参考文献81

  • 1Shu-jia DAI,Gui-fang DOU,Xiao-hong QIAN,Hai-feng SONG,Zhong-ming TANG,De-sheng LIU,Xiu-wen LIU,Liu-meng YANG,Yong-tang ZHENG,Qing LIANG.Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro[J].Acta Pharmacologica Sinica,2005,26(10):1274-1280. 被引量:5
  • 2UNAIDS. AIDS epidemic update; December 2007. Report nr UNAIDS/07.27E/JC1322E. 被引量:1
  • 3http://www.primeboost3 .org. 被引量:1
  • 4Doms RW, Trono D. The plasma membrane as a combat zone in the HIV battlefield [J]. Genes Dev, 2000, 14: 2677-2688. 被引量:1
  • 5Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine [J]. Proc Natl Acad Sci USA, 2003, 100: 10598-10602. 被引量:1
  • 6Chan DC, Fass D, Berger JM, et al. Core structure of gp41 from the HIV envelope glycoprotein [J]. Cell, 1997, 89: 263- 273. 被引量:1
  • 7Naider F, Anglister J. Peptides in the treatment of AIDS [J]. Curr Opin Struct Biol, 2009, 19: 473-482. 被引量:1
  • 8Lu J, Deeks S, Huh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1 infected patients results of a clonal analysis [J]. J Acquir Immune Defic Syndr, 2006, 43: 60-64. 被引量:1
  • 9Clavel F, Hance AL HIV drug resistance [J]. N Engl J Med, 2004, 350: 1023-1035. 被引量:1
  • 10Colman P. New antivirals and drug resistance [J]. Annu Rev Biochem, 2009, 78: 95-118. 被引量:1

共引文献4

同被引文献104

  • 1Eckert D M,Kim P S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region[J].Proc Natl Acad Sci U S A,2001,98(20): 11187-11192. 被引量:1
  • 2Ingallinella P,Bianchi E,Ladwa N A,et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency[J].Proc Natl Acad Sci U S A,2009,106(14): 5801-5806. 被引量:1
  • 3White J M,Delos S E,Brecher M,et al. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme[J].Crit Rev Biochem Mol Biol,2008,43(3): 189-219. 被引量:1
  • 4Bastian A R,Contarino M,Bailey L D,et al. Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions[J].Retrovirology,2013,10: 153. 被引量:1
  • 5Wu Z,Cocchi F,Gentles D,et al. Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in vitro[J].FEBS Lett,2005,579(1): 162-166. 被引量:1
  • 6Mackewicz C E,Yuan J,Tran P,et al. alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors[J].AIDS,2003,17(14): F23-32. 被引量:1
  • 7Wang W,Owen S M,Rudolph D L,et al. Activity of alpha- and theta-defensins against primary isolates of HIV-1[J].J Immunol,2004,173(1): 515-520. 被引量:1
  • 8Chang T L,Francois F,Mosoian A,et al. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition[J]. J Virol,2003,77(12): 6777-6784. 被引量:1
  • 9Gro? A,Brox R,Damm D,et al. Ligand selectivity of a synthetic CXCR4 mimetic peptide[J].Bioorg Med Chem,2015,23(14): 4050-4055. 被引量:1
  • 10Crublet E,Andrieu J P,Vives R R,et al. The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains,including the co-receptor binding site[J]. J Biol Chem,2008,283(22): 15193-15200. 被引量:1

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部